Theriva Biologics (TOVX) just unveiled an update.
Theriva Biologics, Inc. announced promising results from a Phase 1 Trial of VCN-01 for treating pediatric retinoblastoma, with the drug showing potential for broader cancer applications. The trial, which led to an exclusive license from Sant Joan de Déu-Barcelona Children’s Hospital, revealed that VCN-01 was generally well tolerated, with mostly minor treatment-related adverse events, and demonstrated notable antitumor effects. Notably, eye removal was avoided in three children, showcasing VCN-01’s efficacy in preserving vision in cases of this aggressive eye cancer.
For detailed information about TOVX stock, go to TipRanks’ Stock Analysis page.
